Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 225

1.

International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).

Amoroso V, Generali D, Buchholz T, Cristofanilli M, Pedersini R, Curigliano G, Daidone MG, Di Cosimo S, Dowsett M, Fox S, Harris AL, Makris A, Vassalli L, Ravelli A, Cappelletti MR, Hatzis C, Hudis CA, Pedrazzoli P, Sapino A, Semiglazov V, Von Minckwitz G, Simoncini EL, Jacobs MA, Barry P, Kühn T, Darby S, Hermelink K, Symmans F, Gennari A, Schiavon G, Dogliotti L, Berruti A, Bottini A.

J Natl Cancer Inst Monogr. 2015 May;2015(51):90-6. doi: 10.1093/jncimonographs/lgv023.

2.

Bevacizumab plus octreotide and metronomic capecitabine in patients with metastatic well-to-moderately differentiated neuroendocrine tumors: the XELBEVOCT study.

Berruti A, Fazio N, Ferrero A, Brizzi MP, Volante M, Nobili E, Tozzi L, Bodei L, Torta M, D'Avolio A, Priola AM, Birocco N, Amoroso V, Biasco G, Papotti M, Dogliotti L.

BMC Cancer. 2014 Mar 14;14:184. doi: 10.1186/1471-2407-14-184.

3.

Gene expression profiling in breast cancer: a clinical perspective.

Arpino G, Generali D, Sapino A, Del Mastro L, Frassoldati A, de Laurentis M, Paolo P, Mustacchi G, Cazzaniga M, De Placido S, Conte P, Cappelletti M, Zanoni V, Antonelli A, Martinotti M, Puglisi F, Berruti A, Bottini A, Dogliotti L.

Breast. 2013 Apr;22(2):109-20. doi: 10.1016/j.breast.2013.01.016. Epub 2013 Feb 23. Review. Erratum in: Breast. 2016 Feb;25:86. Del Matro, Lucia [corrected to Del Mastro, Lucia].

PMID:
23462680
4.

Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure.

Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A, Dogliotti L, Berardi R, Cappuzzo F, Tagawa ST, Sternberg CN, Jannuzzo MG, Mariani M, Petroccione A, de Wit R.

BJU Int. 2013 Jan;111(1):44-52. doi: 10.1111/j.1464-410X.2012.11404.x. Epub 2012 Aug 29.

5.

Risk factors for disease progression in advanced jejunoileal neuroendocrine tumors.

Panzuto F, Campana D, Fazio N, Brizzi MP, Boninsegna L, Nori F, Di Meglio G, Capurso G, Scarpa A, Dogliotti L, De Braud F, Tomassetti P, Delle Fave G, Falconi M.

Neuroendocrinology. 2012;96(1):32-40. doi: 10.1159/000334038. Epub 2011 Dec 28.

PMID:
22205326
6.

International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).

Berruti A, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A.

J Natl Cancer Inst Monogr. 2011;2011(43):147-51. doi: 10.1093/jncimonographs/lgr037.

PMID:
22043063
7.

Intermediate endpoints of primary systemic therapy in breast cancer patients.

Berruti A, Generali D, Bertaglia V, Brizzi MP, Mele T, Dogliotti L, Bruzzi P, Bottini A.

J Natl Cancer Inst Monogr. 2011;2011(43):142-6. doi: 10.1093/jncimonographs/lgr036.

PMID:
22043062
8.

Molecular oncology and the neoadjuvant setting: the perfect blend for treatment personalization and clinical trial design.

Generali D, Berruti A, Foroni C, Bazzola L, Andreis D, Allevi G, Bersiga A, Dogliotti L, Fox SB, Harris AL, Bottini A.

J Natl Cancer Inst Monogr. 2011;2011(43):67-70. doi: 10.1093/jncimonographs/lgr029.

PMID:
22043044
9.

The treatment of individual patients is more than a trial.

Bottini A, Berruti A, Generali D, Dogliotti L.

J Natl Cancer Inst Monogr. 2011;2011(43):53-4. doi: 10.1093/jncimonographs/lgr022. No abstract available.

PMID:
22043040
10.

Prognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review.

Buttigliero C, Monagheddu C, Petroni P, Saini A, Dogliotti L, Ciccone G, Berruti A.

Oncologist. 2011;16(9):1215-27. doi: 10.1634/theoncologist.2011-0098. Epub 2011 Aug 11. Review.

11.

Psychological distress in men with prostate cancer receiving adjuvant androgen-deprivation therapy.

Saini A, Berruti A, Cracco C, Sguazzotti E, Porpiglia F, Russo L, Bertaglia V, Picci RL, Negro M, Tosco A, Campagna S, Scarpa RM, Dogliotti L, Furlan PM, Ostacoli L.

Urol Oncol. 2013 Apr;31(3):352-8. doi: 10.1016/j.urolonc.2011.02.005. Epub 2011 Jul 30.

12.

Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression.

Panzuto F, Boninsegna L, Fazio N, Campana D, Pia Brizzi M, Capurso G, Scarpa A, De Braud F, Dogliotti L, Tomassetti P, Delle Fave G, Falconi M.

J Clin Oncol. 2011 Jun 10;29(17):2372-7. doi: 10.1200/JCO.2010.33.0688. Epub 2011 May 9.

PMID:
21555696
13.

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

Galsky MD, Chen GJ, Oh WK, Bellmunt J, Roth BJ, Petrioli R, Dogliotti L, Dreicer R, Sonpavde G.

Ann Oncol. 2012 Feb;23(2):406-10. doi: 10.1093/annonc/mdr156. Epub 2011 May 4.

PMID:
21543626
14.

Sorafenib may induce hypophosphatemia through a fibroblast growth factor-23 (FGF23)-independent mechanism.

Bellini E, Pia A, Brizzi MP, Tampellini M, Torta M, Terzolo M, Dogliotti L, Berruti A.

Ann Oncol. 2011 Apr;22(4):988-90. doi: 10.1093/annonc/mdr010. Epub 2011 Feb 14. No abstract available.

15.

The prolyl hydroxylase enzymes are positively associated with hypoxia-inducible factor-1α and vascular endothelial growth factor in human breast cancer and alter in response to primary systemic treatment with epirubicin and tamoxifen.

Fox SB, Generali D, Berruti A, Brizzi MP, Campo L, Bonardi S, Bersiga A, Allevi G, Milani M, Aguggini S, Mele T, Dogliotti L, Bottini A, Harris AL.

Breast Cancer Res. 2011 Feb 3;13(1):R16. doi: 10.1186/bcr2825.

16.

Prevalence of complementary/alternative medicines (CAMs) in a cancer population in northern Italy receiving antineoplastic treatments and relationship with quality of life and psychometric features.

Saini A, Berruti A, Capogna S, Negro M, Sguazzotti E, Picci RL, Campagna S, Dongiovanni V, Dogliotti L, Furlan PM, Ostacoli L.

Qual Life Res. 2011 Jun;20(5):683-90. doi: 10.1007/s11136-010-9795-1. Epub 2010 Nov 16.

PMID:
21080084
17.

Anti-angiogenic effect of tamoxifen combined with epirubicin in breast cancer patients.

Mele T, Generali D, Fox S, Brizzi MP, Bersiga A, Milani M, Allevi G, Bonardi S, Aguggini S, Volante M, Dogliotti L, Bottini A, Harris A, Berruti A.

Breast Cancer Res Treat. 2010 Oct;123(3):795-804. doi: 10.1007/s10549-010-1063-0. Epub 2010 Aug 3.

PMID:
20680681
18.

Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study.

Sperone P, Ferrero A, Daffara F, Priola A, Zaggia B, Volante M, Santini D, Vincenzi B, Badalamenti G, Intrivici C, Del Buono S, De Francia S, Kalomirakis E, Ratti R, Angeli A, Dogliotti L, Papotti M, Terzolo M, Berruti A.

Endocr Relat Cancer. 2010 Apr 21;17(2):445-53. doi: 10.1677/ERC-09-0281. Print 2010 Jun.

19.

Restless legs syndrome and its relationship with anxiety, depression, and quality of life in cancer patients undergoing chemotherapy.

Ostacoli L, Saini A, Ferini-Strambi L, Castronovo V, Sguazzotti E, Picci RL, Toje M, Gorzegno G, Capogna S, Dongiovanni V, Dogliotti L, Furlan PM, Berruti A.

Qual Life Res. 2010 May;19(4):531-7. doi: 10.1007/s11136-010-9614-8. Epub 2010 Feb 27.

PMID:
20195906
20.

The prognostic role of immunohistochemical chromogranin a expression in prostate cancer patients is significantly modified by androgen-deprivation therapy.

Berruti A, Bollito E, Cracco CM, Volante M, Ciccone G, Porpiglia F, Papotti M, Scarpa RM, Dogliotti L.

Prostate. 2010 May 15;70(7):718-26. doi: 10.1002/pros.21104.

PMID:
20087896

Supplemental Content

Loading ...
Support Center